FOI release

FOI2021/00242: UK-CTAP Ivermectin

This request was refused in part, so we didn't provide some of the information the requester asked for. This may include information where we can neither confirm nor deny that we hold it.

Case reference FOI2021/00242

Published 3 September 2021

Request

Request Received: 10 May 2021

I have been advised that the UK COVID-19 Therapeutics Advisory Panel (UK-CTAP) has considered ivermectin as a possible treatment for covid-19 and decided not to prioritise it for inclusion in any of the covid-19 trials. The Department of Health and Social Care has advised that UKRI are the appropriate organisation to request minutes of the UK-CTAP meetings from. Please can you provide any information about

(i) when the evidence about ivermectin was assessed,

(ii) what evidence was included in the review, and

(iii) what determinations were made about that evidence or the potential value of ivermectin as a treatment for covid-19?

If possible, please also provide the minutes of any UK-CTAP meetings in which ivermectin was discussed.

Response

Response Sent: 8 June 2021

Full details of this response are provided in the attached documents.

Documents

• FOI2021-00242 Ivermectin FOI Response.pdf (240.6 KB)
• FOI_Response_Letter_FOI2021_00242_Redacted.pdf (258.7 KB)

This is UK Research and Innovation's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.